Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the publication of a comprehensive review article in Clinical Reviews in Allergy & Immunology providing a state-of-the-art overview of the biology of bradykinin and the bradykinin B2 receptor (B2R), and summarizing the growing body of evidence supporting B2R antagonism as a therapeutic strategy for bradykinin-mediated diseases. Drawing on decades of scientific and clinical research, the article traces the evolution of bradykinin B2 receptor antagonism from foundational discoveries in kinin biology to a clinically validated therapeutic approach.

"The long history of scientific and clinical evidence demonstrates that bradykinin B2 receptor antagonism is a validated and foundational therapeutic approach in the management of bradykinin-mediated angioedema," said Anne Lesage, Ph.D., Chief Early Development Officer of Pharvaris. "A deep understanding of kinin biology and of the roles of bradykinin and the bradykinin B2 receptor in allergic and immunological conditions, such as bronchial asthma, chronic cough, allergic rhinitis, and chronic urticaria, can inform the development of novel therapeutic interventions. Bradykinin B2 receptor antagonism may be a potential viable therapeutic strategy for various diseases; to date, there have been no observations of increased risks of long-term unfavorable effects from the antagonism of the bradykinin B2 receptor. Rooted in scientific expertise, Pharvaris is proud to contribute to the growing knowledge of the roles of bradykinin in the pathogenesis of bradykinin-mediated diseases and of the potential for the antagonism of bradykinin B2 receptor as therapeutic strategy in managing these conditions.”

Advances in understanding kinin biology have enabled the development of mechanism-based treatment approaches. By directly blocking the receptor through which bradykinin exerts its pathological effects, bradykinin B2 receptor antagonists target the main mediator of swelling regardless of the upstream mechanism driving excess bradykinin production and/or bradykinin B2 receptor activity. Clinical experience has supported the therapeutic relevance of this approach and has contributed to a deeper understanding of the role of bradykinin signaling across multiple disease states.

In addition to its established role in HAE, including HAE with normal C1 inhibitor, and AAE-C1INH, growing evidence suggests that bradykinin signaling may contribute to a broader range of immunological and inflammatory disorders, underscoring the potential importance of continued research into bradykinin B2 receptor-targeted therapies.